TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine
Business Wire•19/10/2026•07:00 ET
0
Key Highlights
- ➤$160 million PIPE and approximately $86 million trust account fund transaction
- ➤Approximately $246 million gross proceeds expected, assuming no TCGX shareholder redemptions
- ➤Combined company targets approximately $600 million post-transaction equity value
- ➤Elismetrep Phase 3 migraine trials ongoing, with first results anticipated in mid-2027
- ➤Business combination expected to close in the first quarter of 2027
Expert Statements
Jeff Goater, CEO of TriGemX Bio
“With the anticipated proceeds from this transaction, TriGemX will be positioned to fully fund the Phase 3 development of elismetrep and undertake key commercial readiness activities as we prepare for a potential U.S. launch.”
Jeff Goater, CEO of TriGemX Bio
“Elismetrep is our novel, potential first-in-class acute treatment for migraine.”
Jeff Goater, CEO of TriGemX Bio
“Migraine is one of the most common neurological diseases, and a meaningful percentage of affected patients do not achieve adequate relief from existing therapies.”
Jeff Goater, CEO of TriGemX Bio
“We believe elismetrep will be an important new treatment option for patients suffering with this disease.”
Chen Yu, Founder and Managing Partner of TCGX and CEO of TCGX Acquisition Corp.
“We are thrilled to partner with the team at TriGemX.”
Chen Yu, Founder and Managing Partner of TCGX and CEO of TCGX Acquisition Corp.
“We established TCGX, motivated by the opportunity to support high-potential life sciences companies developing groundbreaking therapies, and TriGemX exemplifies that vision.”
Chen Yu, Founder and Managing Partner of TCGX and CEO of TCGX Acquisition Corp.
“We look forward to supporting the Company as it executes on its next phase of growth.”
TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine
Transaction Includes Concurrent $160 million Private Investment in Public Equity (PIPE) Financing and Expected Gross Proceeds of Approximately $246 million
Get started
Create a free account to read the full story.